Fludarabine (Fludara)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 06:31, 13 May 2012 by Dryang (talk | contribs) (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>")
Jump to navigation Jump to search

General information

Class/mechanism: Purine analog, antimetabolite; fludarabine is converted to the active compound, 2-fluoro-ara-ATP, which inhibits DNA synthesis by inhibiting DNA polymerase alpha, ribonucleotide reductase, and DNA primase. Relatively resistant to deamination by adenosine deaminase. The mechanism of action is not completely characterized and may be multi-faceted.[1][2]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

References

  1. ↑ 1.0 1.1 Fludarabine (Fludara) package insert
  2. ↑ Fludarabine (Fludara) package insert (locally hosted backup)
  3. ↑ Fludarabine (Fludara) patient drug information (Chemocare)
  4. ↑ Fludarabine (Fludara) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Fludarabine_(Fludara)&oldid=1397"